This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Journalology/ Peer Review/ Authorship  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: I am glad that GSK has confirmed that it is moving to produce a worthwhile register of trials, albeit as part of a settlement of the lawsuit brought by Eliot Spitzer, attorney general for the State of New York, discussed in my Commentary.¹ The updated code of the Pharmaceutical Research and Manufacturers of America still does not endorse trial registers. As I also noted, the voluntary register set up in the United Kingdom by the Association of the British Pharmaceutical Industry has not been effective and, in the United States, commercial sponsors of trials have shown themselves willing to ignore a law that requires registration.²

Individual company registers, potentially subject to internal control, can never be the answer; indeed, they are likely to become the problem if they divert lawmakers’ attention from the crying need for a well-funded central register in which all trials are registered and . . . [Full Text of this Article]

Drummond Rennie, MD
drummond_rennie@itsa.ucsf.edu
Deputy Editor, JAMA

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Trial Registration: Ignored to Irresistible
Ronald Krall and Frank Rockhold
JAMA. 2005;293(2):158.
EXTRACT | FULL TEXT  

Trial Registration: A Great Idea Switches From Ignored to Irresistible
Drummond Rennie
JAMA. 2004;292(11):1359-1362.
EXTRACT | FULL TEXT